866-997-4948(US-Canada Toll Free)

Liver Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 596 Pages


Global Markets Directs, \'Liver Cancer - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Cancer. 

Liver Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Liver Cancer.
  • A review of the Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Liver Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Liver Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 9
List of Figures 14
Introduction 15
Global Markets Direct Report Coverage 15
Liver Cancer Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Liver Cancer 17
Liver Cancer Therapeutics under Development by Companies 19
Liver Cancer Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 32
Comparative Analysis 32
Mid Clinical Stage Products 33
Comparative Analysis 33
Early Clinical Stage Products 34
Comparative Analysis 34
Discovery and Pre-Clinical Stage Products 35
Comparative Analysis 35
Liver Cancer Therapeutics - Products under Development by Companies 36
Liver Cancer Therapeutics - Products under Investigation by Universities/Institutes 46
Companies Involved in Liver Cancer Therapeutics Development 50
Bristol-Myers Squibb Company 50
Biocompatibles International plc 51
Boehringer Ingelheim GmbH 52
F. Hoffmann-La Roche Ltd. 53
Celsion Corporation 54
Biogen Idec Inc. 55
AstraZeneca PLC 56
Eli Lilly and Company 57
GlaxoSmithKline plc 58
Tekmira Pharmaceuticals Corp. 59
Inovio Biomedical Corporation 60
Bavarian Nordic A/S 61
MedImmune LLC 62
Daiichi Sankyo Company, Ltd 63
Takeda Pharmaceutical Company Limited 64
Delcath Systems, Inc. 65
Light Sciences Oncology, Inc. 66
ZIOPHARM Oncology, Inc. 67
Novartis AG 68
ImClone Systems Incorporated 69
Chugai Pharmaceutical Co. Ltd 70
Eisai Co., Ltd. 71
Kowa Company, Ltd. 72
Sunway Biotech Co.,Ltd 112
Digna Biotech, S.L. 113
Chipscreen Biosciences Ltd 114
Nerviano Medical Sciences S.r.l. 115
Aegera Therapeutics Inc. 116
Provecs Medical GmbH 117
GenSpera, Inc. 118
Mondobiotech Holding AG 119
Jennerex Biotherapeutics, Inc. 120
BioCancell Therapeutics, Inc. 121
Advenchen Laboratories, LLC 122
AndroScience Corporation 123
Onconova Therapeutics, Inc 124
MolMed S.p.A. 125
Viral Genetics, Inc. 126
Mirna Therapeutics, Inc. 127
Omeros Corporation 128
China Medical System Holdings Limited 129
Welichem Biotech Inc. 130
Oncolys BioPharma Inc. 131
Immunocore Limited. 132
Taiwan Liposome Company 133
Sirnaomics, Inc. 134
CureTech Ltd. 135
Viventia Biotechnologies Inc. 136
AVEO Pharmaceuticals, Inc. 137
Vicus Therapeutics, LLC 138
TRACON Pharmaceuticals, Inc. 139
KAHR medical Ltd. 140
Keystone Nano, Inc. 141
Regulus Therapeutics Inc. 142
Galaxy Biotech, LLC 143
Therapure Biopharma Inc. 144
Polaris Group 145
IkerChem S.L. 146
Gradalis Inc. 147
Liver Cancer - Therapeutics Assessment 148
Assessment by Monotherapy Products 148
Assessment by Combination Products 149
Assessment by Route of Administration 150
Assessment by Molecule Type 153
Drug Profiles 156
tigatuzumab - Drug Profile 156
lenvatinib - Drug Profile 157
RG-7686 - Drug Profile 159
brivanib alaninate - Drug Profile 160
brivanib alaninate - Drug Profile 162
BIIB-022 - Drug Profile 164
nintedanib - Drug Profile 253
peretinoin - Drug Profile 255
peretinoin - Drug Profile 256
BC-821 - Drug Profile 257
BIIB-022 + [sorafenib tosylate] - Drug Profile 318
PEG-BCT-100 - Drug Profile 319
GC-33 + [sorafenib tosylate] - Drug Profile 321
erlotinib hydrochloride + [sorafenib tosylate] - Drug Profile 322
tigatuzumab + [sorafenib tosylate] - Drug Profile 324
tivantinib + [sorafenib tosylate] - Drug Profile 325
TH-302 + [doxorubicin] - Drug Profile 327
veliparib + [temozolomide] - Drug Profile 329
TG-4023 + [flucytosine] - Drug Profile 331
Personalized Peptide Vaccination - Drug Profile 332
131 i-lipiodol - Drug Profile 333
bevacizumab + erlotinib hydrochloride - Drug Profile 334
vvDD-CDSR - Drug Profile 335
miR-34 - Drug Profile 336
Immuncell-LC - Drug Profile 338
silybin phosphatidylcholine - Drug Profile 340
(etodolac + propranolol) - Drug Profile 341
fluorouracil - Drug Profile 343
AFP-Derived Peptide Vaccine - Drug Profile 344
hTERT-Derived Peptide Vaccine - Drug Profile 345
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile 346
Glypican-3 Peptide Vaccine - Drug Profile 348
candesartan cilexetil + celecoxib - Drug Profile 350
GPC3 Targeted Peptide Vaccine - Drug Profile 351
Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 352
Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 353
FANG Vaccine - Drug Profile 354
pexastimogene devacirepvec + [sorafenib tosylate] - Drug Profile 356
TKM-PLK1 - Drug Profile 358
bevacizumab - Drug Profile 360
refametinib + [sorafenib tosylate] - Drug Profile 361
188RE-SSS Lipiodol - Drug Profile 363
phAFP + phGM-CSF + AdVhAFP - Drug Profile 364
fostamatinib disodium - Drug Profile 365
cytokine-induced killer cell (CIK) - Drug Profile 366
TS-1 + Oxaliplatin + Panitumumab - Drug Profile 367
bevacizumab + [dexamethasone acetate] + [floxuridine] - Drug Profile 369
trabectedin + [filgrastim] + [pegfilgrastim] - Drug Profile 371
celecoxib + [epirubicin hydrochloride] - Drug Profile 373
MiR-Rxlet-7 - Drug Profile 374
TRK-560 - Drug Profile 376
MCT-485 - Drug Profile 377
VB6-050 - Drug Profile 378
bavituximab + [sorafenib tosylate] - Drug Profile 379
galunisertib - Drug Profile 380
DC-101 - Drug Profile 381
DC-101 + [sorafenib tosylate] - Drug Profile 383
bevacizumab + erlotinib hydrochloride - Drug Profile 384
AFP-Based Vaccines - Drug Profile 386
(etodolac + propranolol hydrochloride) + [sorafenib] - Drug Profile 387
WBI-2100 + [cisplatin] - Drug Profile 388
WBI-2100 + [gemcitabine hydrochloride] - Drug Profile 389
WBI-2100 + [dacarbazine] - Drug Profile 390
WBI-2100 + [paclitaxel] - Drug Profile 391
DCVax-Liver - Drug Profile 392
(tegafur + gimeracil + oteracil potassium) - Drug Profile 393
DasKloster-001401 - Drug Profile 396
NKP-1339 - Drug Profile 397
NSC-74859 - Drug Profile 398
STP-322 - Drug Profile 399
TBI-302 - Drug Profile 400
Anti miRNA-21 - Drug Profile 401
Anti-CEA Designer T Cells - Drug Profile 402
capecitabine + trastuzumab + [oxaliplatin] - Drug Profile 403
ANZ-100 - Drug Profile 405
HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy - Drug Profile 406
TRC-105 + [sorafenib tosylate] - Drug Profile 407
ColoAd-1 - Drug Profile 408
IMM-160 - Drug Profile 409
CM-101 - Drug Profile 410
BO-110 - Drug Profile 411
Hervlysis - Drug Profile 412
VLI-03B - Drug Profile 413
ImmTAC Targeting Alpha-Fetoprotein - Drug Profile 414
AL-8326 - Drug Profile 415
nemorubicin + [cisplatin] - Drug Profile 416
TACE + Miriplatin - Drug Profile 417
ALF-2111 - Drug Profile 418
H-102 - Drug Profile 419
TBL-0404 - Drug Profile 420
ADV-TK + [ganciclovir] - Drug Profile 421
metformin - Drug Profile 422
STP-916 - Drug Profile 423
Drug For Liver Diseases - Drug Profile 424
KD-018 - Drug Profile 425
ASC-JM.Z1 - Drug Profile 426
Drug Targeting GPR80 - Drug Profile 427
WEE1/CSN5 - Drug Profile 428
IMP-04297 - Drug Profile 430
IMP-03138 - Drug Profile 431
NCL-49 - Drug Profile 432
ONO-7268MX1 - Drug Profile 433
NOV110101 - Drug Profile 434
hydroxychloroquine + sorafenib - Drug Profile 435
pasireotide LAR - Drug Profile 436
TDO Inhibitor - Drug Profile 437
Modified DC Vaccine - Drug Profile 438
microRNA-Based Drug For Liver Cancer - Drug Profile 439
GAL-F2 - Drug Profile 440
Hepatitis B Vaccine - Drug Profile 441
DW-166HC - Drug Profile 443
Drugs Targeting Neddylation - Drug Profile 444
Compound-22 - Drug Profile 445
Drugs for Hepatocellular Carcinoma - Drug Profile 446
Methoxyethylamino-Numonafide - Drug Profile 447
Amino-Numonafide - Drug Profile 448
D-501036 - Drug Profile 449
DCRM-1711 - Drug Profile 451
Liver Cancer Therapeutics - Drug Profile Updates 452
Liver Cancer Therapeutics - Discontinued Products 563
Liver Cancer Therapeutics - Dormant Products 565
Liver Cancer - Product Development Milestones 574
Featured News & Press Releases 574

Appendix 582
Methodology 582
Coverage 582
Secondary Research 582
Primary Research 582
Expert Panel Validation 582
Contact Us 583
Disclaimer 583

List of Table


Number of Products Under Development for Liver Cancer, H1 2013 30
Products under Development for Liver Cancer - Comparative Analysis, H1 2013 31
Number of Products under Development by Companies, H1 2013 33
Number of Products under Development by Companies, H1 2013 (Contd..1) 34
Number of Products under Development by Companies, H1 2013 (Contd..2) 35
Number of Products under Development by Companies, H1 2013 (Contd..3) 36
Number of Products under Development by Companies, H1 2013 (Contd..4) 37
Number of Products under Development by Companies, H1 2013 (Contd..5) 38
Number of Products under Development by Companies, H1 2013 (Contd..6) 39
Number of Products under Development by Companies, H1 2013 (Contd..7) 40
Number of Products under Investigation by Universities/Institutes, H1 2013 42
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 43
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 44
Comparative Analysis by Late Stage Development, H1 2013 45
Comparative Analysis by Mid Clinical Stage Development, H1 2013 46
Comparative Analysis by Early Clinical Stage Development, H1 2013 47
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 48
Products under Development by Companies, H1 2013 49
Products under Development by Companies, H1 2013 (Contd..1) 50
Products under Development by Companies, H1 2013 (Contd..2) 51
Products under Development by Companies, H1 2013 (Contd..3) 52
Products under Development by Companies, H1 2013 (Contd..4) 53
Products under Development by Companies, H1 2013 (Contd..5) 54
Products under Development by Companies, H1 2013 (Contd..6) 55
Products under Development by Companies, H1 2013 (Contd..7) 56
Products under Development by Companies, H1 2013 (Contd..8) 57
Products under Development by Companies, H1 2013 (Contd..9) 58
Products under Investigation by Universities/Institutes, H1 2013 59
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 60
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 61
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 62
Bristol-Myers Squibb Company, H1 2013 63
Biocompatibles International plc, H1 2013 64
Boehringer Ingelheim GmbH, H1 2013 65
F. Hoffmann-La Roche Ltd., H1 2013 66
Celsion Corporation, H1 2013 67
Biogen Idec Inc., H1 2013 68
AstraZeneca PLC, H1 2013 69
Eli Lilly and Company, H1 2013 70
GlaxoSmithKline plc, H1 2013 71
Tekmira Pharmaceuticals Corp., H1 2013 72
Inovio Biomedical Corporation, H1 2013 73
Bavarian Nordic A/S, H1 2013 74
MedImmune LLC, H1 2013 75
Daiichi Sankyo Company, Ltd, H1 2013 76
Takeda Pharmaceutical Company Limited, H1 2013 77
Delcath Systems, Inc., H1 2013 78
Light Sciences Oncology, Inc., H1 2013 79
ZIOPHARM Oncology, Inc., H1 2013 80
Novartis AG, H1 2013 81
ImClone Systems Incorporated, H1 2013 82
Chugai Pharmaceutical Co. Ltd, H1 2013 83
Eisai Co., Ltd., H1 2013 84
Kowa Company, Ltd., H1 2013 85
MDRNA, Inc., H1 2013 86
Ono Pharmaceutical Co., Ltd., H1 2013 87
Pfizer Inc., H1 2013 88
SuperGen, Inc., H1 2013 89
Taiho Pharmaceutical Co., Ltd., H1 2013 90
Silence Therapeutics plc., H1 2013 91
Exelixis, Inc., H1 2013 92
Aduro BioTech, H1 2013 93
Bayer AG, H1 2013 94
4SC AG, H1 2013 95
Can-Fite BioPharma Ltd., H1 2013 96
Ligand Pharmaceuticals Incorporated, H1 2013 97
Basilea Pharmaceutica Ltd., H1 2013 98
MultiCell Technologies, Inc., H1 2013 99
NexMed, Inc., H1 2013 100
Northwest Biotherapeutics, Inc., H1 2013 101
Novogen Limited, H1 2013 102
Cleveland BioLabs, Inc., H1 2013 103
OXiGENE, Inc., H1 2013 104
Peregrine Pharmaceuticals, Inc., H1 2013 105
Curis, Inc., H1 2013 106
ARQULE, INC, H1 2013 107
Alnylam Pharmaceuticals, Inc, H1 2013 108
BTG International Ltd, H1 2013 109
TopoTarget A/S, H1 2013 110
Transgene SA, H1 2013 111
Immuron Limited, H1 2013 112
Progen Pharmaceuticals Limited, H1 2013 113
Dongwha Pharm Co., Ltd., H1 2013 114
Innocell Corporation, H1 2013 115
Threshold Pharmaceuticals, Inc., H1 2013 116
Provectus Pharmaceuticals, Inc., H1 2013 117
Synta Pharmaceuticals Corp., H1 2013 118
BioAlliance Pharma SA, H1 2013 119
Simcere Pharmaceutical Group, H1 2013 120
Transgene Biotek Ltd, H1 2013 121
Raptor Pharmaceuticals Corp., H1 2013 122
Nanobiotix, H1 2013 123
Dicerna Pharmaceuticals, Inc., H1 2013 124
Sunway Biotech Co.,Ltd, H1 2013 125
Digna Biotech, S.L., H1 2013 126
Chipscreen Biosciences Ltd, H1 2013 127
Nerviano Medical Sciences S.r.l., H1 2013 128
Aegera Therapeutics Inc., H1 2013 129
Provecs Medical GmbH, H1 2013 130
GenSpera, Inc., H1 2013 131
Mondobiotech Holding AG, H1 2013 132
Jennerex Biotherapeutics, Inc., H1 2013 133
BioCancell Therapeutics, Inc., H1 2013 134
Advenchen Laboratories, LLC, H1 2013 135
AndroScience Corporation, H1 2013 136
Onconova Therapeutics, Inc, H1 2013 137
MolMed S.p.A., H1 2013 138
Viral Genetics, Inc., H1 2013 139
Mirna Therapeutics, Inc., H1 2013 140
Omeros Corporation, H1 2013 141
China Medical System Holdings Limited, H1 2013 142
Welichem Biotech Inc., H1 2013 143
Oncolys BioPharma Inc., H1 2013 144
Immunocore Limited., H1 2013 145
Taiwan Liposome Company, H1 2013 146
Sirnaomics, Inc., H1 2013 147
CureTech Ltd., H1 2013 148
Viventia Biotechnologies Inc., H1 2013 149
AVEO Pharmaceuticals, Inc., H1 2013 150
Vicus Therapeutics, LLC, H1 2013 151
TRACON Pharmaceuticals, Inc., H1 2013 152
KAHR medical Ltd., H1 2013 153
Keystone Nano, Inc., H1 2013 154
Regulus Therapeutics Inc., H1 2013 155
Galaxy Biotech, LLC, H1 2013 156
Therapure Biopharma Inc., H1 2013 157
Polaris Group, H1 2013 158
IkerChem S.L., H1 2013 159
Gradalis Inc., H1 2013 160
Assessment by Monotherapy Products, H1 2013 161
Assessment by Combination Products, H1 2013 162
Assessment by Stage and Route of Administration, H1 2013 165
Assessment by Stage and Molecule Type, H1 2013 168
Liver Cancer Therapeutics - Drug Profile Updates 465
Liver Cancer Therapeutics - Discontinued Products 576
Liver Cancer Therapeutics - Discontinued Products (Contd..1) 577
Liver Cancer Therapeutics - Dormant Products 578
Liver Cancer Therapeutics - Dormant Products (Contd..1) 579
Liver Cancer Therapeutics - Dormant Products (Contd..2) 580
Liver Cancer Therapeutics - Dormant Products (Contd..3) 581
Liver Cancer Therapeutics - Dormant Products (Contd..4) 582
Liver Cancer Therapeutics - Dormant Products (Contd..5) 583
Liver Cancer Therapeutics - Dormant Products (Contd..6) 584
Liver Cancer Therapeutics - Dormant Products (Contd..7) 585
Liver Cancer Therapeutics - Dormant Products (Contd..8) 586

List of Chart


Number of Products under Development for Liver Cancer, H1 2013 30
Products under Development for Liver Cancer - Comparative Analysis, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Investigation by Universities/Institutes, H1 2013 41
Late Stage Products, H1 2013 45
Mid Clinical Stage Products, H1 2013 46
Early Clinical Stage Products, H1 2013 47
Discovery and Pre-Clinical Stage Products, H1 2013 48
Assessment by Monotherapy Products, H1 2013 161
Assessment by Combination Products, H1 2013 162
Assessment by Route of Administration, H1 2013 163
Assessment by Stage and Route of Administration, H1 2013 164
Assessment by Molecule Type, H1 2013 166
Assessment by Stage and Molecule Type, H1 2013 167

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *